Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics (Nasdaq: ANTX) has adopted a duration stockholder rights plan set to expire on August 15, 2025. This decision comes after the company discovered a rapid accumulation of 19.3% of its common stock by BML Investment Partners, L.P. The plan aims to ensure fair treatment of all stockholders and protect against coercive tactics aimed at gaining control without paying a full premium.
Key points of the rights plan include:
- Distribution of one preferred stock purchase right per common stock share to stockholders of record on August 29, 2024
- Exercise price of $6.50 per right under certain circumstances
- Board's ability to redeem rights at $0.01 per right before 20% ownership threshold is reached
- Provisions for stockholders to purchase additional shares at a discount if a person or group acquires 20% or more of common stock
AN2 Therapeutics (Nasdaq: ANTX) reported Q2 2024 financial results and recent business updates. Key points include:
- Cash position: $104.5 million as of June 30, 2024, expected to fund operations through 2027
- Termination of epetraborole Phase 2/3 study in TR-MAC lung disease due to similar sputum culture conversion rates between treatment arms
- Pipeline advancement: Two development programs expected to enter clinical trials in 2025
- Q2 2024 financials: R&D expenses $12.1 million, G&A expenses $3.7 million, net loss $14.4 million
Despite setbacks in the MAC lung disease study, AN2 remains focused on advancing its boron chemistry platform in infectious diseases and oncology.
AN2 Therapeutics (Nasdaq: ANTX) announced that the EBO-301 Phase 2/3 study evaluating epetraborole for treatment-refractory Mycobacterium avium Complex (MAC) lung disease will be discontinued. The Phase 2 part met its primary objective of demonstrating a higher patient-reported outcome (PRO)-based clinical response rate (39.5% vs. placebo 25.0%; p=0.19), but sputum culture conversion at Month 6 was similar between treatment arms (13.2% vs. 10.0%; p=0.64). No significant safety concerns were noted.
The company will shift focus to its boron chemistry platform and other pipeline programs, including Chagas disease and melioidosis. Restructuring and cost savings are expected to extend the cash runway through 2027. Further evaluation of the EBO-301 study results will inform future development of epetraborole for NTM lung disease.
AN2 Therapeutics (Nasdaq: ANTX) released its Q1 2024 financial results and recent business updates. The company is focusing on the Phase 2/3 trial of epetraborole for treatment-refractory Mycobacterium avium Complex (TR-MAC). Phase 2 topline results are expected in August 2024. Phase 3 enrollment is paused due to lower than expected efficacy, not safety issues. R&D expenses rose to $14.7M from $12.0M YoY, while G&A expenses decreased to $3.6M from $4.1M. The net loss increased to $16.6M from $15.3M YoY. Cash reserves stood at $118.1M as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.